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Posttranscriptional gene silencing allows sequence-specific control of gene expression. Specificity is guar-
anteed by small antisense RNAs such as microRNAs (miRNAs) or small interfering RNAs (siRNAs). Func-
tional miRNAs derive from longer double-stranded RNA (dsRNA) molecules that are cleaved to pre-miRNAs
in the nucleus and are transported by exportin 5 (Exp 5) to the cytoplasm. Adenovirus-infected cells express
virus-associated (VA) RNAs, which are dsRNA molecules similar in structure to pre-miRNAs. VA RNAs are
also transported by Exp 5 to the cytoplasm, where they accumulate. Here we show that small RNAs derived
from VA RNAs (svaRNAs), similar to miRNAs, can be found in adenovirus-infected cells. VA RNA processing
to svaRNAs requires neither viral replication nor viral protein expression, as evidenced by the fact that
svaRNA accumulation can be detected in cells transfected with VA sequences. svaRNAs are efficiently bound
by Argonaute 2, the endonuclease of the RNA-induced silencing complex, and behave as functional siRNAs, in
that they inhibit the expression of reporter genes with complementary sequences. Blocking svaRNA-mediated
inhibition affects efficient adenovirus production, indicating that svaRNAs are required for virus viability.
Thus, svaRNA-mediated silencing could represent a novel mechanism used by adenoviruses to control cellular
or viral gene expression.
Virus-associated (VA) RNAs are noncoding polymerase III-
transcribed 160-nucleotide RNAs that accumulate in the cy-
toplasm of adenovirus-infected cells (32). Adenovirus sero-
types 2 and 5, like most human adenovirus serotypes, express
two VA RNAs, VAI and VAII, whereas others carry a single
VA RNA more related to VAI (32). While VAI is more abun-
dant and has been better studied, little is known about VAII,
which might carry out nonessential functions (27, 48) and com-
pensate in part for the lack of VAI in VAI-mutated adenovirus
(3, 4, 48). The main function of VAI is the blockade of RNA-
dependent protein kinase (PKR), an interferon-inducible
serine-threonine protein kinase activated in infected cells as
part of the antiviral response. Adenovirus infection, as is the
case with other viruses, could lead to the production of double-
stranded RNA (dsRNA) through symmetrical transcription of
the viral genome. dsRNA activates PKR, which phosphorylates
the  subunit of eukaryotic initiation factor 2 (eIF-2) (21).
Phosphorylation converts eIF-2-GDP from a substrate to an
inhibitor of its exchange factor eIF2B, so the complex eIF2 ·
GTP-Met · tRNA cannot be formed and translation initiation
fails, leading to the shutoff of protein synthesis (9). However,
adenovirus-produced VA RNAs bind to and block PKR acti-
vation and therefore protein synthesis inhibition (40). Also,
VAI stabilizes ribosome-associated viral mRNAs, which could
lead to enhanced levels of protein synthesis (39).
VA RNAs are single-stranded RNA molecules that fold into
dsRNA (32). Although the nucleotide sequences of VA RNAs
are poorly conserved between adenovirus serotypes, their sec-
ondary structure has been well maintained and can generally
be divided into a terminal stem, a panhandle apical stem, and
a more structured central domain (Fig. 1) (15, 32, 36). Muta-
genic studies indicate that the apical stem-loop is required for
binding to PKR and that the central domain is involved in the
inhibition of PKR activation (35–37). The terminal stem is
essential for binding to Exp 5, which mediates VA transport to
the cytoplasm (16, 17). Although Exp5 binds dsRNA in a
sequence-independent manner (5), the terminal stem is par-
tially conserved across adenovirus serotypes, as it includes se-
quences essential for polymerase III transcription (32).
Minihelix RNAs and pre-microRNAs (pre-miRNAs) are
also dsRNA molecules transported by Exp 5 to the cytoplasm
before being further processed by Dicer to small interfering
RNAs (siRNAs) or miRNAs, respectively (16, 18, 30, 38, 49).
siRNAs and miRNAs are 21- to 25-nucleotide sequences that
bind the RNA-induced silencing complex (RISC) to guide
RNA silencing. RNA silencing allows the control of cellular
gene expression and works as an alternative immune mecha-
nism against viral infections in plant and insect cells (24).
Recently, increasing evidence has supported the notion that
RNA silencing plays an antiviral role in vertebrates also. Thus,
expression of the retrovirus primate foamy virus type 1
(PFV-1) is downregulated by the cellular miRNA miR32 (23).
Also, human immunodeficiency virus type 1 (HIV-1) and sim-
ian virus 40 (SV40) encode viral siRNA or miRNA precursors
in their genomes (2, 46). Concomitantly, PFV-1 and HIV-1
evade cell control, expressing Tas and Tat proteins, respec-
tively, that inhibit RNA silencing (2, 23). Similarly, other virus-
encoded proteins, such as influenza virus NS1 protein or vac-
cinia virus E3L, affect the functionality of the miRNA pathway
in heterologous systems (26). Notably, VAI RNAs can bind
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Dicer in vitro and have been described as competitors in the
processing of both pre-miRNAs and short hairpin RNAs (29).
Even if all these results indicate that some vertebrate viruses
may need to block cellular silencing to guarantee their viability,
viruses could also use the cellular silencing machinery to con-
trol gene expression. Thus, viral miRNAs that could regulate
expression of both host and viral genes have been described in
several viruses (6, 41, 42, 46). In the case of SV40, it has been
shown that a viral miRNA could be involved in reducing sus-
ceptibility to cytotoxic T cells (46).
In this report we show that VAI RNAs are processed to
small RNAs (svaRNAs) in adenovirus-infected cells and in VA
RNA-expressing cells. These svaRNAs interact with Argo-
naute 2, the functional endonuclease from RISC, and inhibit
the expression of reporter genes with complementary se-
quences. This suggests that they could behave as functional
siRNAs or miRNAs. Finally, blockade of VAI-derived small
RNAs decreases adenovirus production, indicating that
svaRNAs could control the expression of cellular or viral genes
required for adenovirus viability.
MATERIALS AND METHODS
Cell lines and viruses. Human 293 and HeLa cells and mouse fibroblast 3T3
cells were obtained from the ATCC. All cell lines were cultured in Dulbecco’s
modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum,
1% penicillin-streptomycin, and 2 mM L-glutamine. Cell lines were cultured at
37°C under a 5% CO2 atmosphere. All cell culture reagents were obtained from
Gibco-BRL/Life Technologies. Plasmids were transfected using calcium phos-
phate as described elsewhere (14). For stable transfections, clones were selected
in 1 mg/ml of G418 (GIBCO) 3 days after transfection. Transfection with 2-O-
methyl (2ome) oligonucleotides (Sigma) was performed using Lipofectamine
2000 (Invitrogen) following the recommendations of the supplier. In brief, 100
pmol of oligonucleotide was mixed with 0.4 g of pGL3-Promoter, which ex-
presses luciferase and served as a transfection control, 0.2 g of the Renilla
constructs (see below), and 1.2 g of plasmid pAdvantage (pAdv) or a control
plasmid. The DNA mix was incubated with 4 l of Lipofectamine 2000 in 1 ml
of Opti-MEM (Gibco) and added to 3.5  105 cells. Cells were analyzed 2 days
posttransfection. 2-O-Methyl oligonucleotides used were 2omeMut (CGACGU
CAGACAACGGGGGAGCGCUCCUUUU), 2omeAS3 (AAAAGGAGCGC
UCCCCCGUUGUCUGACGUCG), 2omeAS3Mut (AAAAAGAGCGAUCC
CACGUUGUCUGACGUCG), 2omeAS5 (AAUUUAUCCACCAGACCAC
GGAAGAGUGCCC), and 2omeAS5Mut (AAUUUAUCCACAAGACCACA
GAAGAGUACCC).
Adenoviruses were amplified in 293 cells, purified by double cesium chloride
gradient ultracentrifugation, and desalted in a G50 Sephadex column. The ad-
enovirus titer was calculated with an AdenoX rapid titer kit (BD Biosciences) or
by limiting dilution. 293 cells were infected in DMEM–2% fetal bovine serum
with wild-type adenovirus type 5 (AdWT) or a mutant virus that does not express
VA RNAs (AdVA) (7, 48) at a multiplicity of infection (MOI) of 3. Infection
of 3T3 cells was carried out under the same conditions but at an MOI of 100.
Similarly, stable HeLa cell lines were infected at an MOI of 30. Transfected
HeLa cells were infected, at an MOI of 30, 1 day after transfection and were
analyzed for luciferase expression 2 days postinfection. 293 cells transfected with
2-O-methyl oligonucleotides were infected 1 day posttransfection, and the virus
titer was evaluated from the cell supernatant or from both the cell supernatant
and the pellet at 3 days postinfection.
Plasmids. pAdvantage (Promega) contains VAI and VAII genes from adeno-
virus type 2 under the control of their own promoters. pFAgo2 expresses Argo-
naute 2 fused to Flag and hemagglutinin (HA) tags and was kindly donated by T.
Tusch (34). pGL3-Promoter (Promega) expressing luciferase was used as a
transfection control. pRL-SV40 (Promega) was used to construct the plasmids
that express VAI RNA sequences in the 3 untranslated region (3 UTR) of
Renilla mRNA. Appropriate oligonucleotide sequences were cloned into the
XbaI site (in lowercase letters) of pRL-SV40 to obtain pRLVAint (tctagaTCG
AACCCCGGTCGTCCGCCATGATctaga), pRL5VA (tctagACCCTTGCGAA
TTTATCCACCAGACCACGGAAGAGTGCCCGCTctaga), and pRL3VA (tc
tagAGGAGCGCTCCCCCGTTGTCTGACGTCGCtctaga), which bind their
complementary sequences at the central part, 5 end, and 3 end of VAI RNA,
respectively. Sequences were cloned in the sense or antisense orientation as
indicated. In pRL5VAx2 and pRL3VAx2, two identical sequences were cloned in
tandem at the XbaI site. Positive clones were verified by DNA sequencing (ABI
Prism 310 genetic analyzer; Perkin-Elmer).
Protein analysis. Renilla and firefly luciferase activity was quantified using the
Dual Luciferase System (Promega) as previously described (14) in a Berthold
Luminometer (Lumat LB 9507). Western blots were hybridized to the anti-Flag
(Flag) antibody M2 (Sigma), diluted 1:1,000, and were visualized by using an
anti-mouse antibody coupled to peroxidase (Sigma), diluted 1:1,000, and en-
hanced chemiluminescence (Perkin-Elmer). Immunoprecipitations were done by
mixing extracts obtained from 106 cells with 10 l of agarose-coupled Flag
antibody (Sigma) or a control antibody. After binding for 2 h at 4°C, beads were
washed three times in 1 ml of immunoprecipitation buffer (13), and depleted
extracts and beads were evaluated by Western blotting or were used to isolate
RNA. Adequate amounts were loaded on the gel so comparisons could be made
directly.
Preparation and analysis of RNA. Total RNA was purified using guanidium
thiocyanate as described elsewhere (8). Nuclear and cytoplasmic RNA was pu-
rified as previously described (12). To isolate small RNA, 30 g of total RNA was
FIG. 1. Predicted structure of VAI RNA from adenovirus type 2. The sequences that hybridize to oligonucleotides 5VA, 3VAn, 3VApe,
5apVA, and 3apVA are indicated. The structure can be divided into a terminal stem, a central domain, and an apical stem. The sequence of VAI
RNA from adenovirus type 5 is identical except for two nucleotides in the apical stem (A66G and G72U).
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separated in a 15% polyacrylamide gel, and the RNA that ran between 20 and 30
bp was isolated. RNA from polyacrylamide, input extracts, or fractions bound or
not bound to antibody beads, was isolated as previously described (13).
For Northern blotting, 20 g of total RNA was mixed with 1 volume of loading
sample buffer (95% formamide, 1 mM EDTA, 0.025% bromophenol blue and
xylene cyanol dyes) and boiled at 95°C for 3 min. Samples were loaded onto a
15% polyacrylamide gel, and RNAs were separated by electrophoresis. Labeled
DNA molecular weight markers that had been compared previously to the sizes
of small RNAs such as let-7, miR16, and miR21 were also loaded. The gel was
transferred to a Hybond  membrane (Amersham Pharmacia Biotech) in 25
mM NaxHPO4 (pH 6.5) and hybridized overnight to labeled oligonucleotides in
5% sodium dodecyl sulfate (SDS)–200 mM NaxHPO4 (pH 6.5). The membrane
was then washed three times for 30 min with 2 SSC (1 SSC is 0.15 M NaCl
plus 0.015 M sodium citrate) and 0.1% SDS and exposed to Biomax film (Kodak)
or to a Cyclone screen (Perkin-Elmer). Oligonucleotides were labeled with T4
polynucleotide kinase (New England Biolabs) in the presence of [-32P]ATP
(13). Oligonucleotide U6 (5 TGCTAATCTTCTCTGTATCGT 3) was used as
a loading control. Oligonucleotides 5VA (5 ATCCACCAGACCACGGAAGA
3) and 3VAn (5 AGGAGCGCTCCCCCGTTGT 3) bind to the 5 and 3 ends
of VAI RNAs, respectively. Oligonucleotides 5apVA (5 TCGAACCCCGGT
CGTCCG 3) and 3apVA (5 ACGGCGGACGGCCGGAT 3) bind to se-
quences in the apical stem of VAI RNA, as shown in Fig. 1.
Primer extensions were done as described previously (13). Oligonucleotides
used were 5VA, 3VApe (AAAAGGAGCGCTCCCCC), let-7 (AAAACTAT
ACAACCTACTAC), and U6. Six picomoles of -ATP-labeled oligonucleotides
was incubated with 3 g of total RNA or with the small or immunoprecipitated
RNAs described above. Only 0.25 g of RNA was used in the primer extensions
with oligonucleotide U6. Samples were loaded onto a 14% polyacrylamide gel
and separated by electrophoresis. Gels were dried and exposed to a screen that
was developed in a Cyclone phosphorimager (Perkin Elmer).
RESULTS
The VAI RNA terminal stem is processed into svaRNAs. To
test whether VA RNAs could be processed to small RNAs, we
used Northern blotting to analyze RNAs isolated from 293
cells that were either mock infected or infected with AdWT or
AdVA (7, 48). The Northern blot was hybridized to oligonu-
cleotides 5VA, 3VAn, 5apVA, and 3apVA, which recognize
the longer dsRNA regions of VAI (Fig. 1) or to oligonucleo-
tides that bind to similar sequences of VAII RNAs. We de-
tected two small RNAs from the terminal stem of VAI RNA
that were named svaRNAs (Fig. 2A). As expected, svaRNAs
were detected only in AdWT-infected cells (Fig. 2A, lane 3),
not in uninfected cells or in cells infected with the VA-deleted
adenovirus (Fig. 2A, lanes 1 and 2). The size of the signal
obtained with oligonucleotide 3VA was 23 nucleotides (Fig.
2A, lane 3, upper panel). Oligonucleotide 5VA detected a
weaker signal of approximately 29 nucleotides, which is higher
than the regular 21 to 25 nucleotides observed for most
miRNAs (Fig. 2A, lane 3, middle panel). However, we could
not detect small RNAs that correspond to the apical stem of
VAI RNAs or to any VAII sequences (data not shown). Since
VAII RNAs are expressed 10- to 100-fold less than VAI RNAs
(44), a putative signal could exist that is below the detection
limit of the technique.
VA RNAs are first detected in the cytoplasm of infected
cells 18 h after infection (20). A Northern blot of RNA isolated
at different times postinfection showed that svaRNAs were
also clearly detected at 18 h postinfection (Fig. 2B, lane 5).
svaRNA accumulation then increased as infection proceeded,
following a pattern similar to that of cytoplasmic accumulation
of VA RNAs (Fig. 2B, lanes 6 to 8). Thus, the highest accu-
mulation is observed at 72 h postinfection, which corresponds
to the end of the adenovirus cycle in 293 cells.
Neither viral replication nor viral protein expression is re-
quired for VA processing. Even if pre-miRNAs are similar in
structure to VA RNAs, the latter are longer and include a
stem-loop-rich central domain. Thus, we hypothesized that a
productive adenovirus infectious cycle or viral proteins could
be required for VA RNA processing into svaRNAs. Because
mouse cells are nonpermissive for adenovirus replication, we
isolated RNA from 3T3 mouse fibroblasts infected with ade-
novirus at different times. Northern blot analysis of the RNAs
indicated that even in the absence of viral replication,
svaRNAs accumulated after 18 h of infection (Fig. 3A, lanes 5
to 8). In agreement with the results obtained with 293 cells, we
detected small RNAs only with sequences corresponding to the
terminal stem of VAI RNA.
Several adenovirus proteins have been implicated in the
transcription of VA RNAs. E1B is a transcription activator,
while E1A acts as an activator in infected cells and as a re-
pressor in transfected cells (45). However, svaRNAs were de-
tected by Northern blotting in E1-expressing 293 cells trans-
fected with pAdv, which contains VA genes from adenovirus
type 2 (Fig. 3B, lane 3). Similarly, HeLa or 3T3 cells trans-
fected with pAdv accumulated svaRNAs (Fig. 3B, lane 5) (data
not shown), indicating that adenovirus proteins are not re-
quired for VAI small RNA processing.
Characterization of svaRNAs. Intact VAI RNAs can be de-
tected in transfected or infected cells even at late times of
infection. Thus, not all VAI RNA is cleaved into svaRNA. To
calculate the efficiency of VAI RNA processing, RNA isolated
from 293 cells infected with adenovirus was analyzed by North-
ern blotting with oligonucleotide 3VAn. The result is shown in
Fig. 4A, where the svaRNA part (lower panel) was exposed 10
times longer than the VAI RNA part (upper panel). The
amounts of VAI RNA and 3svaRNA were quantified, indi-
cating that only 2 to 5% of the total VAI RNA was processed
into svaRNA. Similar results were observed for HeLa cells
FIG. 2. svaRNAs are found in adenovirus-infected 293
cells.(A) Northern blotting was carried out with RNA isolated from
293 cells that were either mock infected or infected with AdWT or
AdVA. (B) 293 cells were mock infected or infected with wild-type
adenovirus, and Northern blotting was done with RNAs isolated at
different hours postinfection (hpi) as indicated at the top. The North-
ern blots were hybridized to oligonucleotide 3VAn (upper panels),
oligonucleotide 5VA (middle panels), or a U6 snRNA oligonucleo-
tide as a loading control (lower panels). The number of nucleotides is
indicated on the left. The positions of 3svaRNA, 5svaRNA, and U6
snRNA are indicated.
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transfected with pAdv or for infected 3T3 cells (data not
shown).
Given the low processing efficiency, we decided to analyze if
the svaRNAs were functional, so we first characterized them
further. Thus, their 5 ends were analyzed by primer extension.
Oligonucleotide 3VApe, a short oligonucleotide that interacts
with the last 17 nucleotides of VAI RNA (Fig. 4C), could be
preferentially extended 6 nucleotides when hybridized to RNA
isolated from HeLa cells transfected with pAdv (Fig. 4B, lanes
3 and 4, upper panel). Since the total length of the 3svaRNA
is 23 nucleotides (Fig. 2 and 3), we concluded that the
3svaRNA sequence comprises the last 23 nucleotides of VAI
RNA (Fig. 4C). Similarly, oligonucleotide 5VA (Fig. 4C)
could be extended 6 nucleotides to the 5 end of VAI RNA
(Fig. 4B, lanes 3 and 4, middle panel). A fainter extension of 9
nucleotides was also detected that could correspond to VAI
RNAs initiated in a less efficient transcription start site (31).
However, these 5VA bands could represent mostly intact VAI
RNAs. Therefore, small RNAs were isolated from the 20- to
30-nucleotide band excised from a polyacrylamide gel where
control RNA or RNA from pAdv-transfected cells had been
separated. When the small RNAs were used in the primer
extension reactions, both oligonucleotides 3VA and 5VA
were extended 6 nucleotides (Fig. 4B, lanes 6 and 7, upper and
lower panels). This result confirms that 5svaRNAs comprise
the first 29 nucleotides of VAI RNA (Fig. 4C), as indicated by
Northern blotting (Fig. 2 and 3). Finally the subcellular local-
ization of VA RNAs was addressed. RNA was isolated from
nuclear and cytoplasmic fractions of HeLa cells transfected
with pAdv, and primer extension was carried out. Proper frac-
tionation was verified by hybridization to U6 snRNAs and let-7
probes (data not shown). svaRNAs accumulate preferentially
in the cytoplasmic fraction, even if 20% of these RNAs can
FIG. 3. svaRNAs are produced in the absence of viral proteins or
adenovirus replication. (A) Nonpermissive 3T3 cells were infected as
for Fig. 2B, and Northern blotting was carried out accordingly. (B) 293
or HeLa cells were either mock transfected, transfected with pAdvan-
tage (T), or infected (only 293 cells) with wild-type adenovirus (I).
RNA was isolated and analyzed by Northern blotting by hybridization
to oligonucleotide 3VAn, 5VA, or U6 snRNA as indicated. The
number of nucleotides is indicated on the sides. The positions of
3svaRNA, 5svaRNA, and U6 snRNA are indicated.
FIG. 4. Characterization of svaRNAs. (A) Efficiency of svaRNA processing. RNA isolated from mock-infected or infected (I) 293 cells was
analyzed by Northern blotting by hybridization to oligonucleotide 3VAn. Single and double (2) amounts of RNA were used to ensure proper
quantitation. Positions of intact 160-nucleotide VAI RNA and 3svaRNA are indicated. Note that the lower panel shows a 10-times-longer
exposure. (B) Sequence and localization of svaRNAs. RNA was isolated from total, nuclear, or cytoplasmic fractions of HeLa cells that were either
mock transfected or transfected with pAdv. Total RNA was separated in a polyacrylamide gel, and 20- to 30-nucleotide small RNAs were purified.
Buffer (Oligo) (lanes 1, 5, and 8), total RNA (lanes 2 to 4), small RNAs (lanes 6 and 7), nuclear RNA (lane 9), or cytoplasmic RNA (lane 10)
was analyzed by primer extension with oligonucleotide 3VApe (upper panel) or 5VA (middle panel) or with a U6 snRNA oligonucleotide as a
loading control (lower panel). A double amount of RNA was used where indicated (2). The primer extension corresponding to 3svaRNA,
5svaRNA, and U6 snRNA is indicated. The number of nucleotides is given on the left. (C) Schematic representation of svaRNAs. Sequences of
5 and 3 svaRNAs are shown together with the oligonucleotides used for primer extension.
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also be found in the nucleus (Fig. 4B, lanes 9 and 10, upper and
lower panels).
Functional miRNAs bind the RISC endonuclease Ago2 (28,
34, 43). To analyze if svaRNAs also bind Ago2, we made use of
a plasmid that encodes Ago2 sequences fused to a Flag tag
(pFAgo2 [34]). Expression of Flag-tagged Ago2 (FAgo2) could
easily be detected by Western blotting with an anti-Flag anti-
body in pFAgo2-transfected HeLa cells (Fig. 5A, lane 2). Also,
using immunoprecipitation, tagged Ago2 protein could be
found bound to the anti-Flag antibody but not bound to a
control antibody (Fig. 5A, lanes 3 to 6). Thus, extracts from
HeLa cells cotransfected with pAdv and either a control plas-
mid or pFAgo2 were immunoprecipitated with an anti-Flag or
a control antibody. The input, supernatant, and bound frac-
FIG. 5. svaRNAs coimmunoprecipitate with Ago2. (A) Flag-tagged Ago2 protein can be efficiently immunoprecipitated with an anti-Flag
antibody. Extracts from cells transfected with pAdv or cotransfected with pAdv and a plasmid that encodes a Flag-tagged Ago2 protein
(pAdvFAgo2) were immunoprecipitated with a control antibody (Mock) or with an anti-Flag antibody (Flag). Input, bound, and unbound
fractions were separated by SDS-polyacrylamide gel electrophoresis, and Western blotting was carried out with anti-Flag antibody. The position
of Flag-tagged Ago2 (FAgo2) is indicated. (B) Ago2 binds svaRNAs. RNA was isolated from the fractions described for panel A, and a primer
extension reaction was carried out. The oligonucleotides used revealed let-7 miRNA (upper panel), 3svaRNA (middle panel), or 5svaRNA (lower
panel). Ub, unbound fractions; B, bound fractions; I, input; O, oligonucleotide-only reaction. The primer extension corresponding to let-7,
3svaRNA, and 5svaRNA is indicated. (C) Characterization of HeLa clones expressing Flag-tagged Ago2. Extracts from HeLa cells or cells
transfected with a plasmid expressing FAgo2 transiently (FAgo2) or stably (clones C1 to C4) were immunoprecipitated with Flag antibody. Total
extracts (upper panel) or extracts bound to Flag (lower panel) were analyzed by Western blotting with an Flag antibody. The position of FAgo2
is indicated. (D) svaRNAs from adenovirus-infected cells bind Ago2. Extracts from HeLa cells transfected with pAdv and pFAgo2 (pAdvFAgo2)
or from adenovirus-infected HeLa clones 1 (C1  AdWT) and 4 (C4  AdWT) that express Ago2 were immunoprecipitated with an Flag or a
control antibody. RNA was isolated from the input, bound, and unbound fractions of the immunoprecipitates, and a primer extension reaction was
carried out.
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tions of each immunoprecipitation were used to isolate RNA
that was then analyzed by primer extension using oligonucle-
otide let-7, 3VApe, or 5VA. As expected, let-7 and miR16,
abundant endogenous miRNAs in HeLa cells, were detected
bound to the anti-Flag antibody in cells transfected with
pFAgo2 (Fig. 5B, lane 10, upper panel) (data not shown) but
were not detected bound to a control antibody or to any anti-
body in cells lacking FAgo2 (Fig. 5B, lanes 3, 5, and 8, upper
panel) (data not shown). 3svaRNA and 5svaRNA were de-
tected in the same fractions as let-7, indicating that svaRNAs
bind to Ago2 (Fig. 5B, lane 10, middle and lower panels). The
amount of RNA extended with oligonucleotide 5VA in the
fraction bound to Ago2 was very small, although clearly de-
tectable (Fig. 5B, compare lanes 9 and 10). This result supports
the possibility that only 5svaRNA is bound to Ago2, since
oligonucleotide 5VA detects both intact VAI RNA and
5svaRNA. The amount of 3svaRNA bound to FAgo2 was
greater than the amount of let-7 (Fig. 5B, compare lanes 9 and
10 in upper and middle panels). This could be due to a rela-
tively low efficiency of transfection. Thus, we isolated stable
HeLa cell lines expressing FAgo2 as detected by Western blot-
ting or by immunoprecipitation with an anti-Flag antibody
(Fig. 5C, clones 1 and 4 in lanes 3 and 6). These stable trans-
formants showed that Ago2 binding efficiencies to let-7 and
3svaRNA were similar (data not shown) (Fig. 5D). The stable
clones were also used to analyze the binding to Ago2 of
svaRNAs produced in adenovirus-infected cells. The result,
shown in Fig. 5D, is similar to that shown in Fig. 5B. Both
3svaRNA and 5svaRNA were detected in the same fractions
as let-7, indicating that svaRNAs produced in adenovirus-in-
fected cells also bind to Ago2 (Fig. 5D, lanes 11 and 16). This
binding is specific, as the terminal ends of other abundant and
structured RNAs, such as U1 snRNA or 5S rRNA, were not
found in the Ago2 fractions (data not shown).
Analysis of svaRNA function in the control of gene expres-
sion. svaRNAs could control the expression of cellular or viral
genes in infected cells. To test if svaRNAs can interfere with
gene expression, we constructed plasmids expressing Renilla
luciferase (RL) mRNA that include different sequences from
VAI RNAs. The sequences chosen hybridize to the apical stem
of VAI RNAs (nucleotides 40 to 65; RLVAint) or to the 5
(RL5VA) or 3 (RL3VA) terminal stem. The target sequences
were included once or twice (RLxVAx2) in the 3 UTR of RL
mRNA and in the sense (RLs) or antisense (RLas) orientation
(Fig. 6A). Note that the sense sequence of one end of VAI
RNA contains the antisense sequence of the other end with
two mutations that disrupt base pairing (RLasMut) (11) (Fig.
1). HeLa cells were cotransfected with each Renilla construct
together with pAdv or a control plasmid. A firefly luciferase
expression plasmid was also included in all cases as a transfec-
tion and expression control. Luciferase activities were mea-
sured 2 days posttransfection, and RL values were corrected by
firefly luciferase activity, even if the latter showed similar levels
in all samples, indicating that transfection efficiencies were
homogeneous. The percentage of RL expression relative to the
expression of RL without VA sequences was plotted (Fig. 6B).
Cotransfection of the RL constructs with the control plasmid
yielded similar luciferase activities in all cases, indicating that
the VA sequences introduced did not alter RL mRNA expres-
sion, stability, or translation (Fig. 6B). pAdv is commercialized
to increase expression from cotransfected plasmids, as VAI
expression should block PKR activation and therefore increase
gene expression (22, 47). pAdv transfections need to be opti-
mized to obtain a VA-mediated increase of expression. Using
our regular cotransfection conditions, expression of Renilla was
not increased by the presence of VA RNAs except in the case
of RLas5VAx2Mut, which was expressed at 1.8-fold-higher
levels (Fig. 6B). However, expression of Renilla with VA ter-
minal antisense sequences decreased in the presence of pAdv,
suggesting that small VA RNAs could be functional interfering
RNAs. The highest decrease was observed in Renilla genes
containing 1 or 2 copies of the VAI 3-end sequence (Fig. 6B).
This inhibition is specific, as we did not observe decreased
expression of RLas3VAx2Mut or RLas5VAx2Mut, whose
binding to 3svaRNA or 5svaRNA, respectively, is abrogated
by two disrupting mutations (Fig. 1). Similar results have been
observed upon transfection of 293 cells or 3T3 cells (data not
shown) or upon infection with wild-type adenovirus (Fig. 6C).
Again, RL expression from RL or RLVAint constructs was
very similar in wild-type adenovirus-infected cells. However,
expression from Renilla genes containing 1 or 2 copies of the
VAI 3-end sequence was reduced to approximately 20% (Fig.
6C). No differences were observed when cells were infected
with an adenovirus that does not express VA sequences
(AdVA; Fig. 6C).
Blocking of svaRNAs affects adenovirus production. If
svaRNAs are essential for adenovirus viability, mutations in
the terminal stem of VAI should result in defects in viral
amplification. It has been demonstrated that VAI RNA func-
tions primarily to block PKR function, as eIF2 mutants that
FIG. 6. Expression of RL mRNAs that bind to VAI RNA terminal
sequences is inhibited in cells expressing VAI RNA. (A) Schematic
representation of the reporter genes used for this study. VAI RNA
(diagramed at the top) sequences were expressed in the 3 UTR of RL.
Sequences chosen were VA internal sequences (VAint) and either the
sense (s) or antisense (as) 5 (5VA) or 3 (3VA) end. Note that the
sense sequence of one end of VAI RNA contains the antisense se-
quence of the other end with two mutations that disrupt base pairing
(Mut). Sequences were inserted once or twice (x2). (B) HeLa cells
were cotransfected with the RL constructs shown and a control plas-
mid (Mock) or pAdv, and luciferase activity was measured 2 days
posttransfection. (C) HeLa cells transfected with the RL constructs
shown in panel A were infected with AdWT or AdVA. Luciferase
activity was measured 3 days posttransfection. Percentages of RL ex-
pression relative to the expression of the unmodified RL construct are
indicated. Error bars, standard deviations. Results shown are averages
from four different experiments.
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cannot be phosphorylated complement the growth defect of an
adenovirus deleted in the VAI gene (10). However, substitu-
tions of the sequences at the 3 termini of VAI were intro-
duced into adenoviruses that express VAI molecules that are
able to be properly folded and transported to the cytoplasm of
infected cells. Even though these VAI 3-end mutants should
be functional in blocking PKR, the mutant viruses showed a
10-fold decrease in viral replication (3). This indicates that the
3 end of VAI could play a different role in adenovirus viability.
Unfortunately, mutations in the 5 end of VAI affect VAI
RNA expression, since these sequences overlap with the poly-
merase III promoter sequences (32).
An alternative to evaluating the role of svaRNAs in adeno-
virus infection would be to block svaRNA interactions with
hybridizing 2ome modified oligonucleotides (19, 33). 2ome
oligonucleotides were designed with antisense sequences to
3svaRNA (2omeAS3) or 5svaRNA (2omeAS5). Similar se-
quences with three point mutations that abrogate binding to
3svaRNA (2omeAS3Mut) or 5svaRNA (2omeAS5Mut)
were used as negative controls. A control oligonucleotide was
also designed with sense sequences of 3svaRNA (2omeMut).
To evaluate the functionality of 2ome oligonucleotides,
2omeAS3 or 2omeMut was cotransfected with pAdv and an
RL containing 3svaRNA antisense sequences (RLas3VA).
Cells transfected with the 2omeMut oligonucleotide showed
RL expression similar to that of mock-transfected cells. How-
ever, cells transfected with the 2omeAS3 oligonucleotide
showed increased RL activity, suggesting that 3svaRNA-me-
diated inhibition had been partially blocked (Fig. 7A).
Thus, cells transfected with 2ome oligonucleotides were in-
fected with AdWT or AdVA, and 3 days postinfection the
supernatant was collected to titer adenovirus with the AdenoX
rapid titer kit (Fig. 7B). The result shows that AdWT produc-
tion was higher in cells with functional svaRNAs. Cells trans-
fected with any of the 2omeMut control oligonucleotides pro-
duce more AdWT than cells transfected with the 2ome
oligonucleotides with antisense sequences to 3svaRNA or
5svaRNA. Also, AdWT production was more affected in cells
with nonfunctional 3svaRNA than in cells with blocked
5svaRNA (Fig. 7B). However, no differences were observed in
virus titer when the cells transfected with the 2ome oligonu-
cleotides were infected with AdVA, which lacks VA se-
quences (data not shown). This shows that 2omeAS3 and
2omeAS5 do not affect adenovirus production in the absence
of VA sequences. Finally, a similar result was obtained when
virus was titered from both supernatant and cellular fractions,
indicating that the difference in AdWT production is not at the
level of virus cell release (data not shown).
DISCUSSION
We have shown that the terminal stem of VAI RNA is
processed to 5 and 3 svaRNAs. Even though the processing is
not very efficient, these svaRNAs interact with the silencing
machinery and are capable of inhibiting gene expression. Dur-
ing the process of review of our work, a complementary study
was published concluding that not only VAI RNA but also
VAII RNA is processed by Dicer to small RNAs (1). In agree-
ment with our results, the authors also show that these small
RNAs produced in vitro can inhibit gene expression when
cotransfected with a sensor reporter and that extracts from
infected cells can cleave reporters with 5 or 3 VA sequences.
These data lead to the suggestion that VA-derived small RNAs
comprise the terminal stem of VA RNAs (1).
Our experiments extend further in the analysis of the
svaRNAs. The combination of Northern blotting and primer
extension with purified small RNAs suggests that the
3svaRNA sequence comprises the last 23 nucleotides of VAI
RNA while 5svaRNAs consist of the first 29 nucleotides (Fig.
2, 3, and 4B). Thus, the length of 3svaRNA is similar to that
of cellular miRNAs. However, 5svaRNA is 29 nucleotides
long, too long compared with regular miRNAs. This greater
length could be explained if the stem formed by nucleotides 24
to 30 of VAI RNA forces an aberrant cleavage of Dicer (Fig.
1). Also, we generally observe higher accumulation of
3svaRNA than of 5svaRNA (Fig. 2, 3, and 4B). This higher
accumulation correlates with higher binding to Ago2 (Fig. 5B
and D), better inhibition of target reporter gene expression
(Fig. 6B), and stronger involvement in adenovirus production
(Fig. 7B).
The VAI RNA terminal stem is processed to svaRNAs that
bind Ago2 (Fig. 5) and inhibit the expression of reporter genes
with complementary sequences (Fig. 6B and C). This inhibition
is partly suppressed with antisense 2ome oligonucleotides (Fig.
7A). Also, blocking of svaRNAs drastically affects AdWT pro-
duction (Fig. 7B), and adenoviruses that express properly
folded VAI RNA with 3-end mutations show a decrease in
viral replication (3). These data strongly suggest that svaRNAs
use the silencing machinery to inhibit gene expression and
therefore improve adenovirus viability. svaRNA-mediated in-
FIG. 7. Blocking of svaRNAs affects adenovirus viability.
(A) svaRNA-mediated inhibition can be blocked with antisense 2-O-
methyl oligonucleotides. Cells were transfected with pAdv and
RLas3VA either alone (Mock) or in combination with 2-O-methyl
oligonucleotides with sense (2omeMut) or antisense (2omeAS3) se-
quences of 3svaRNA. Luciferase expression, measured 3 days post-
transfection, is plotted as the percentage of activity relative to an
unmodified RL construct. (B) Cells transfected with 2-O-methyl oli-
gonucleotides with 3svaRNA sense sequences (2omeMut), with
5svaRNA (2omeAS5) or 3svaRNA (2omeAS3) antisense se-
quences, or with mutated 5svaRNA (2omeAS5Mut) or 3svaRNA
(2omeAS3Mut) antisense sequences were infected with wild-type ad-
enovirus. Cell supernatants were collected at 3 days postinfection, and
virus titers were evaluated and plotted. Error bars, standard deviations.
Results shown are averages from three different infections.
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hibition of gene expression should occur early during infection,
as adenovirus infection suppresses RNA interference (RNAi)
at late times of infection, probably to avoid silencing of viral
genes (1, 29). This blockade of RNAi could also be caused by
saturation of the cellular silencing pathway with svaRNAs.
Alternatively, svaRNAs could control gene expression by other
means. svaRNAs could act as miRNAs that bind to the termi-
nal stem of VAI RNA and aid localization to ribosomes, where
VAI RNA is found at late times of infection (39).
Future work is required to identify svaRNA target genes.
Database searches have failed to find genes with perfect ho-
mology to VAI terminal sequences, suggesting that inhibition
could affect the translation of target genes and not their
mRNA stability. Recently, several highly valuable bioinfor-
matic tools, such as TargetScan, have been described that scan
for putative microRNA target mRNAs (25). A TargetScan
search on the Ensembl release 31.35d 3 UTR database (based
on the NCBI 35 assembly of the human genome) using
3svaRNA as the test sequence yielded a list of 198 putative
targets. Also, we modified the TargetScan program to admit
the 29-nucleotide 5svaRNAs, and the result was a list of 863
putative targets. Nine putative targets were found in both com-
parisons. Several cellular processes are well represented in the
lists of putative targets. However, some of them are more
abundant, as indicated by the presence of 21 phosphatases, 42
kinases, 11 ubiquitin-related proteins, and 35 G binding pro-
teins or proteins related to small GTPases (such as Rho, Ras,
or Ran). There are 38 factors related to transcription and 7
related to translation initiation. Also, there are cellular factors
involved in VA RNA processing or function. Thus, there are
three genes related to silencing and four genes related to
interferon activation, including 2-5oligoadenylate synthase
and RNase L. Unfortunately, the list of targets cannot be cured
by comparison to orthologue sequences in mice or rats, be-
cause adenovirus is nonreplicative in rodents. We need to find
alternative methods for target identification. This is of great
importance not only for the understanding of adenovirus biol-
ogy but because it may have implications for human health
care. First-generation adenovirus vectors are widely proposed
for gene therapy approaches. Thus, several human gene ther-
apy trials are ongoing with these vectors. However, first-gen-
eration adenovirus vectors express normal levels of VA RNAs
(data not shown), so they may induce a change in cellular gene
expression whose toxicity needs to be evaluated.
Viral miRNAs have been detected in several viruses such as
HIV-1, SV40, and herpesviruses including Epstein-Barr virus
(EBV) (2, 6, 41, 42, 46). Even if EBV miRNAs are encoded
elsewhere in the genome, EBV and other animal viruses ex-
press dsRNA structures similar to VA RNAs, which could also
be processed into miRNAs. Thus, processing of VA RNA-like
structures may represent a new mechanism used by several
viruses to produce viral miRNAs. Such miRNAs should not be
detected with miRNA prediction protocols, as they normally
scan sequences of 50 to 100 nucleotides, while VAI-like RNAs
are longer (41). Regarding viral miRNA functionality, it has
been demonstrated only for SV40 viral miRNAs, which are
involved in reduced susceptibility to cytotoxic T cells (46). This
work shows that adenovirus svaRNAs could have a functional
role in viral production. Therefore, RNA silencing could be
used by several viruses to control viral or cellular gene expres-
sion in order to improve virus viability.
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